The company is also presenting new research on computational treatment selection at American cancer and healthcare conferences.
The company’s technology analyzes a tumor’s complete molecular profile and ranks targeted therapies based on available scientific evidence. Its commercial proposition is that genomic tests generate more information than physicians can routinely use, while treatment decisions are still often based on a single mutation or biomarker.
Genomate says its system evaluates more than 200 approved treatments and over 1,000 drugs in clinical development. It is designed to support clinical decision-making rather than serve as an autonomous treatment system, with oncologists retaining responsibility for final decisions.
“Our goal with the development of AI-based precision oncology technology is not to replace doctors, but to give them a tool with which they can select the most effective treatment for the patient more accurately,” says István Peták, founder of Genomate and Oncompass Medicine.
Genomate Health and Oncompass Medicine merged at the beginning of 2026, according to the company, creating a business with operations in Europe and the United States and a research center in Hungary. Genomate also launched a genomics-based cancer second-opinion service for U.S. patients in June.
The technology grew out of research Peták and his Hungarian team began more than two decades ago. Instead of matching one drug to one genetic alteration, the computational model aggregates evidence linking detected alterations, molecular targets and available therapies. It then assigns scores intended to indicate which treatments are more likely to benefit a patient.
A 2021 study published in npj Precision Oncology retrospectively applied the system to molecular and outcome data from 113 patients in the SHIVA01 clinical trial. Patients receiving high-scoring targeted therapies had a median progression-free survival of 3.95 months, compared with 1.95 months among those receiving low-scoring treatments. Disease control rates were also higher in the high-score group.
A further study published in May 2025 examined real-world data from 111 lung cancer patients treated in Hungary. Median progression-free survival was 32 months for 19 high-score targeted treatment lines, compared with eight months for other treatments. Patients who received at least one high-score therapy also had a higher five-year survival rate than those receiving only lower-scoring targeted treatments or standard chemotherapy.
The findings support the model’s ability to identify associations between its scores and treatment outcomes, but do not amount to definitive evidence from a prospective randomized trial of Genomate-guided care. The lung cancer analysis was retrospective, involved a relatively small cohort and reflected decisions made by physicians and molecular tumor boards, who also considered reimbursement, guidelines, comorbidities and drug availability.
Clinical decision-support software must demonstrate consistent value across cancer types, healthcare systems and patient populations. Adoption also depends on integration with genomic laboratories, hospital workflows, reimbursement systems and regulatory requirements.
Genomate presented additional analyses at the American Association for Cancer Research’s 2026 annual meeting on April 17–22, at the San Diego Convention Center in San Diego, California, and at the C3 Davos Silicon Valley Healthcare Summit on April 27, in Sunnyvale, also in California, where seven speakers were selected from 135 applicants.
Genomate’s strategy now moves beyond research collaborations toward direct clinical services and institutional partnerships. Its second-opinion offering in the United States combines an existing next-generation sequencing report with computational analysis and review by oncology specialists. The company is marketing the technology to oncologists, laboratories, cancer centers, and biopharmaceutical companies.
For patients, the service addresses a gap between receiving a complex genomic report and determining whether its findings alter treatment options. For healthcare providers, the business case is based on standardizing a process often handled by molecular tumor boards, whose recommendations can differ between institutions.
Importantly, the platform is not intended to diagnose cancer or replace clinical judgment. Genomate’s product information states that qualified healthcare professionals must interpret its reports and that the software is not intended to diagnose, treat or cure disease independently.
Peták says the now merged organization intends to retain its Hungarian scientific base while broadening its international reach.
“We are not merely expanding our geographical presence, but building a global precision oncology center that has played a pioneering role in all three of our key technological breakthroughs: from the first diagnostic tests and molecular tumor profiling to the first clinically validated computational solution,” he says. “We are building on Hungarian innovation, but now with international experts in one team and an international presence.”
The company’s Hungarian research operation works with Semmelweis University, István Széchenyi University and Péter Pázmány Catholic University. Genomate also participates in the Mayo Clinic accelerator ecosystem, the CancerX initiative and Nvidia’s Inception program. Its investors include technology entrepreneurs and Hungarian investment groups, although the company has not published detailed revenue, valuation or financing figures.
That lack of financial disclosure makes it difficult to assess the scale of the business relative to the scientific claims surrounding it. The next stage will depend on converting published evidence, conference recognition and partnerships into recurring clinical and enterprise revenue.
For Genomate, the opportunity is the growing amount of genomic data generated in cancer care. The risk is that clinical adoption will move more slowly than technological development. Broader use will require prospective validation, regulatory clarity, reimbursement and evidence that the system improves outcomes and resource allocation.
The company’s 2026 expansion gives the Hungarian-developed platform a larger commercial base. Its longer-term position, however, will be determined by clinical validation and adoption rather than awards or conference selection.
This article was first published in the Budapest Business Journal print issue of September 4, 2026.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
